Results of portal systemic shunts in XXXX .

@entity1 @entity6582 @entity75 @entity5 @entity843 @entity260 @entity1778 @entity3181 @entity6323 @entity715
Nine @entity1 with @entity3181 ( @entity3181 ) were treated by a portal systemic shunt. One had @entity715 of the superior mesenteric vein (SMV) and another had @entity6323 (IVC). All other @entity1 had a marked stenosis of the retrohepatic IVC with caval pressure ranging from 12 to 24 mmHg (mean: 17 mmHg). Seven @entity1 had an interposition mesocaval shunt using an autologous jugular vein. The @entity1 with a thrombosed SMV had a portoatrial shunt. The @entity1 with an obstructed IVC had a cavoatrial shunt after an erroneous portacaval shunt had failed to relieve @entity843 . There were no operative deaths and no major @entity260 . One @entity1 died 19 months after operation of acute @entity1778 complicating @entity6582 rubra vera. All other @entity1 were alive and well 8 months to 6 years after operation. None of them had @entity75 . These results suggest several comments: Portal systemic shunts are a good treatment for @entity3181 and have a low operative risk. The mesocaval shunt is an efficient procedure, even when there is stenosis of the IVC with high caval pressure; shunts to the right atrium should be performed only in the case of complete obstruction or inaccessibility of the IVC. The long-term prognosis is excellent, except in @entity1 with potential @entity5 . Therefore, portal systemic shunts should be indicated early in @entity1 with symptomatic @entity3181 .
